# Efficacy and Safety of JAK Inhibitors in Systemic Sclerosis-associated Interstitial Lung Disease

> **NCT05177471** · — · WITHDRAWN · sponsor: **Central Hospital, Nancy, France**

## Conditions studied

- Systemic Sclerosis
- Interstitial Lung Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05177471
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-01-19
- **Primary completion:** 2024-08-26
- **Final completion:** 2024-08-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** no eligible patients
- **Last updated:** 2024-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05177471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05177471, "Efficacy and Safety of JAK Inhibitors in Systemic Sclerosis-associated Interstitial Lung Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05177471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*